|
Ekta Kapoor to reveal India’s youngest heart throb
Daily Bhaskar In fact, he is the hero of the next film being produced by Ekta Kapoor. The producer is confident about her new discovery that she has already named him India’s youngest heart throb who is all set to flutter millions of hearts across the globe … |
Orgenesis Announces Management Changes – Virtual-Strategy Magazine (press release)
|
Orgenesis Announces Management Changes
Virtual-Strategy Magazine (press release) The Company believes that converting the diabetic patient’s own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. |
Competition affects who gets a liver transplant – Fox News
Competition affects who gets a liver transplantFox NewsWhen more than one center has patients on the same donor list, the centers have an incentive to get organs for as many of their own patients as possible, wrote researchers, whose report appeared in…
Orgenesis Announces Management Changes – MarketWatch (press release)
|
Orgenesis Announces Management Changes
MarketWatch (press release) The Company believes that converting the diabetic patient’s own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. |
A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma … – 7thSpace Interactive (press release)
A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma …7thSpace Interactive (press release)She experienced a relapse 19 months later with involvement of the retroperitoneal lymph nodes, and commenced treatment with rituximab an…
Research and Markets: Biogen-Idec's and Facet Biotech's Daclizumab: Can It … – PharmiWeb.com (press release)
|
Research and Markets: Biogen-Idec’s and Facet Biotech’s Daclizumab: Can It …
PharmiWeb.com (press release) Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an … |
Research and Markets: Biogen-Idec's and Facet Biotech's Daclizumab: Can It … – Fort Mills Times
|
Research and Markets: Biogen-Idec’s and Facet Biotech’s Daclizumab: Can It …
Fort Mills Times Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an … |
Research and Markets: Biogen-Idec's and Facet Biotech's Daclizumab: Can It Compete in the Increasingly Crowded …
Research and Markets has announced the addition of the “Biogen-Idec’s and Facet Biotech’s Daclizumab: Can It Com
Sleep apnea may protect heart attack patients – Times of India
Times of IndiaSleep apnea may protect heart attack patientsTimes of IndiaBut findings of a new study carried out by scientists from Technion-Israel Institute of Technology have shown that some heart attack patients can actually benefit from mild to mod…
Immucor to AcquireLIFECODES Business – Private Equity Hub (press release)
Immucor to AcquireLIFECODES BusinessPrivate Equity Hub (press release)The LIFECODES business specializes in pre-transplant human leukocyte antigen (HLA) typing and screening to ensure the most compatible match between patient and donor, as well as post…